A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Google Cloud's commitment to AI-powered cancer research and Sun Pharma's partnership with a music icon.

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on AbbVie (ABBV – Research Report) today and set a price target of $239.00. The ...

(Reuters) -AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition-related expenses. The company expects adjusted profit in the range of ...

Hull, United Kingdom 2024 New York Stock Exchange 2024 500+ sites will spark blue PD Avengers - Global Alliance to End Parkin ...

(Reuters) -Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay ...

Novartis, Pfizer, Janssen, BioMarin, Eli Lilly, MSD and AbbVie are just some of the global pharmaceutical companies with a major presence in Cork, dotted around our harbour or in East or North Cork, ...

On Monday, Bank of America (NYSE:BAC) (BofA) increased its price target on AbbVie (NYSE:ABBV) to $167 from $165, while maintaining... ByInvesting.com • Feb 05, 2024 Goldman Sachs raises AbbVie stock ...

So, you want to invest in AbbVie (ABBV 2.33%) because it's a promising dividend-paying stock, and you also want to receive $1,000 per year in dividend income from it. How many shares should you buy?

Elahere secured full approval from the US Food and Drug Administration last year. Credit: © AbbVie. US-based pharmaceutical company AbbVie has reported the final ...

AbbVie Inc. (NYSE:ABBV) entered the obesity race last week when it in-licensed GUB014295 (also called GUBamy) from Denmark-based Gubra. The candidate is a long-acting amylin analog for the ...